Top videos | SnacTube

Home
Articles

Top videos

All Time

Today

This week

This month

This year

Leukemia Cure? Patient Still Cancer-Free 11 Years After Innovative Treatment administrator 17 Views • 2 years ago

Doug Olson may be 75 years old, but he feels great. He's still cancer-free 11 years after he potentially faced death from a blood cancer called chronic lymphocytic leukemia. At that time, his doctors informed him that the treatments he had been trying we not working.

"Terrified is probably the best word to describe it," Olson told CBNNews.

Feeling he had nothing to lose, Doug agreed to an experimental treatment developed at the University of Pennsylvania called CAR-T therapy. It uses the patient's own immune system, specifically the T-cells.

Read the full story from CBN's Lorie Johnson:
https://www1.cbn.com/cbnnews/h....ealth/2022/june/leuk

Download the free CBN News App: http://cbnnews.com/app

SUBSCRIBE to the CBN News Channel for more:
http://youtube.com/c/CBNnewson....line/?sub_confirmati

What's coming up next? Have a look at our program guide: https://www.youtube.com/redirect?q=http%3A%2F%2Fwww1.cbn.com%2Fcbnnews%2Fnewschann&redir_token=3Xja-7LE5ZQebEu1fn-B5ib34tN8MTU3OTg4MjMzMkAxNTc5Nzk1OTMy&v=P0mHVeNNfDw&event=video_description

CBN features 24-hour TV news from a Christian perspective. The CBN News Channel provides independent news programming to an underserved audience to enlighten, entertain and inspire Christians around the world. Comments below do not necessarily reflect the views of CBN.

Share this live feed with your friends and family:
https://www.youtube.com/c/CBNnewsonline

Like us on Facebook: https://www.facebook.com/cbnnews/
Like us on Twitter: https://twitter.com/CBNNews
Follow us on Instagram: https://www.instagram.com/cbnnews/

Contact News Editors: https://www.youtube.com/redirect?q=https%3A%2F%2Fwww1.cbn.com%2Fcontact%2Fcontact-&redir_token=3Xja-7LE5ZQebEu1fn-B5ib34tN8MTU3OTg4MjMzMkAxNTc5Nzk1OTMy&v=P0mHVeNNfDw&event=video_description

Questions about other CBN programs: https://www.youtube.com/redirect?q=https%3A%2F%2Fwww1.cbn.com%2Fcontact%2Fcontact-&redir_token=3Xja-7LE5ZQebEu1fn-B5ib34tN8MTU3OTg4MjMzMkAxNTc5Nzk1OTMy&v=P0mHVeNNfDw&event=video_description

Questions about supporting CBN?
http://www1.cbn.com/cbn-partners (and) https://www.youtube.com/redirect?q=https%3A%2F%2Fsupport.google.com%2Fyoutube%2F%3Fp&redir_token=3Xja-7LE5ZQebEu1fn-B5ib34tN8MTU3OTg4MjMzMkAxNTc5Nzk1OTMy&v=P0mHVeNNfDw&event=video_description

Questions about Helping the Home Front? Call: 757-226-2333
https://www.youtube.com/redirect?q=https%3A%2F%2Fwww1.cbn.com%2F700club%2Fhelping-&redir_token=3Xja-7LE5ZQebEu1fn-B5ib34tN8MTU3OTg4MjMzMkAxNTc5Nzk1OTMy&v=P0mHVeNNfDw&event=video_description

#breakingnews #politicalnews #christiannews #christian #christianity #church #breakingnews #cbnnews

Nivolumab/Ipilimumab Approved In Europe For Frontline Unresectable Malignant Pleural Mesothelioma administrator 17 Views • 2 years ago

Nivolumab And Ipilimumab Approved In Europe For Frontline Unresectable Malignant Pleural Mesothelioma
➡️ http://MesotheliomaUSA.net

The European Commission has approved the dual immunotherapy combination of nivolumab and ipilimumab for use in the frontline treatment of adults with unresectable malignant pleural mesothelioma.

The regulatory decision was based on findings from the phase 3 CheckMate-743 trial (NCT02899299), which showed that the doublet resulted in a 26% reduction in the risk of death compared with platinum-based, standard-of-care chemotherapy (HR, 0.74; 96.6% CI, 0.60-0.91; P = .002). The median OS with the immunotherapy regimen was 18.1 months (95% CI, 16.8-21.4) vs 14.1 months (95% CI, 12.4-16.2) with chemotherapy, meeting the primary end point of the trial. The 2-year OS rates in the investigative and combination arms were 41% and 27%, respectively.

This is the first positive phase 3 trial of an immunotherapy in the frontline treatment of malignant pleural mesothelioma, according to Bristol Myers Squibb.

“After many years of limited progress in the treatment of malignant mesothelioma, we saw an important clinical benefit for patients with nivolumab plus ipilimumab in the CheckMate-743 trial,” Paul Baas, MD, PhD, of the Department of Thoracic Oncology at the Netherlands Cancer Institute and the University of Leiden, stated in a press release. “With the EC approval of this dual immunotherapy combination, patients and doctors will now have a new treatment option that has shown significant improvements in survival to manage this resistant disease.”

In the open-label, multicenter phase 3 CheckMate-743 trial, investigators examined nivolumab plus ipilimumab vs chemotherapy, which was either pemetrexed and cisplatin or carboplatin, in 605 patients with previously untreated malignant pleural mesothelioma.

Notably, patients who had interstitial lung disease, active autoimmune disease, any conditions that required systemic immunosuppression, or active brain metastases, were not eligible for enrollment. Participants were stratified based on histology, epithelial vs non-epithelial disease, and gender.

Study participants were randomized to receive either nivolumab at 3 mg/kg biweekly plus ipilimumab at 1 mg/kg every 6 weeks (n = 303), or cisplatin at 75 mg/m2 or carboplatin AUC 5 plus pemetrexed at 500 mg/m2 in 21-day treatment cycles for 6 cycles. Patients continued to receive treatment until progressive disease or intolerable toxicity; if in the doublet immunotherapy arm, they received up until 24 months.

The primary end point of the trial was OS in all randomized patients, while other key end points included progression-free survival (PFS), objective response rate (ORR), and duration of response (DOR) per blinded independent central review and RECIST criteria. Other exploratory end points comprised safety, pharmacokinetics, immunogenicity, and patient-reported outcomes.

Additional data from the trial showed that the median PFS with nivolumab plus ipilimumab was shorter than that observed with chemotherapy, at 6.8 months vs 7.2 months, respectively (HR, 1.00; 95% CI, 0.82-1.21). However, the 1-year PFS rates in the investigative and control arms were 30% and 16%, respectively, while the 2-year PFS rates were 24% and 7%, respectively.

The ORRs between the investigative and control arms were similar, at 40% (95% CI, 34.1%-45.4%) and 43% (95% CI, 37.1%-48.5%), respectively. Moreover, the median DOR achieved with the doublet was 11.0 months (95% CI, 8.1-16.5) vs 6.7 months with chemotherapy (95% CI, 5.3-7.1). Thirty-two percent of the responders who received the immunotherapy combination experienced a response that continued at 2 years vs just 8% who received the chemotherapy. The median time to response was 2.7 months with the doublet and 2.5 months with the chemotherapy.

Additional data presented during the 2020 International Association for the Study of Lung Cancer’s World Conference on Lung Cancer Virtual Presidential Symposium showed that the 1-year OS rate with nivolumab plus ipilimumab was 68% vs 58% with chemotherapy. The 2-year OS rates in the investigative and control arms were 41% and 27%, respectively.

Notably, the survival benefit of the dual immunotherapy regimen was observed across all prespecified subgroups, irrespective of epithelioid disease or PD-L1 expression.

Regarding safety, nivolumab plus ipilimumab was determined to be manageable using established adverse effect management protocols.

Nivolumab And Ipilimumab Approved In Europe For Frontline Unresectable Malignant Pleural Mesothelioma
https://www.youtube.com/watch?v=DA_yr5WbOM8
https://www.youtube.com/channe....l/UCOVJwa1zpdmoeq2db

#nivolumab #opdivo #ipilimumab #yervoy #malignant #pleuralmesothelioma #europeancommission #immunotherapy

🔗 https://www.onclive.com/view/n....ivolumab-ipilimumab-

Understanding Ovarian Cancer administrator 17 Views • 2 years ago

To download this animation and up to 7 more, employees of hospitals, universities and libraries can sign up for a FREE trial to the Nucleus Medical Art Library: http://nmal.nucleusmedicalmedi....a.com/free-trial-mem

#OvarianCancer #Cancer #Ovary

MEDICAL ANIMATION TRANSCRIPT: You or someone you care about has been diagnosed with ovarian cancer. This video will help you understand the disease and how it may affect you. Women have two ovaries. They are on either side of the uterus. The ovaries are part of the reproductive system that makes and stores eggs. Ovaries also make the hormones estrogen and progesterone. The two fallopian tubes are attached to the uterus. After an egg is released from the ovary, it passes through one of the tubes to the uterus. The ovaries lie close to the peritoneum. The peritoneum is the inner lining of the abdomen that also covers most of the organs in your abdomen and pelvis. Most ovarian cancers begin in the outer layer of the ovary. This is called epithelial ovarian cancer. Cancer occurs when cells grow out of control. Abnormal cells continue to divide and may spread to other parts of the body. Germ cell tumors are another type of ovarian cancer. They start in the cells that make eggs. Stromal tumors are a third type. They begin in the supporting tissue of the ovaries where hormones are made. A number of factors may raise your risk of epithelial ovarian cancer. One risk factor is age. Half of ovarian cancers happen in women age 63 or older. Obesity is another risk factor. Women with a body mass index of 30 or greater have a higher risk. The risk is also higher for women who had their first baby after age 35, or who have never had a baby. Taking hormone therapy with estrogen alone after menopause may raise your risk. And having a family history of ovarian and certain other cancers can also increase risk. Ovarian cancer may have no early symptoms. Symptoms of ovarian cancer are often vague. When symptoms do appear, they may include pain in the pelvis or abdomen, gas or bloating, irregular menstrual bleeding, feeling that you always need to urinate, constipation, and back pain. However, in most cases these symptoms are caused by conditions that are not ovarian cancer. If you have ovarian cancer, your doctor will need to determine the subtypes of ovarian carcinoma, the grade, and the stage or progression of the disease to help plan your treatment. Each grade is based on how different the cancer cells look compared to normal ovary cells under a microscope. The higher the grade, the more aggressive the cancer is. Each stage for ovarian cancer is based on how far cancer cells have spread from where they began. Stage 1 means the cancer is only within the ovaries. At Stage 2 the cancer has spread to other organs, but it's still within the pelvis. In Stage 3 cancer has spread beyond the pelvis to either the peritoneum or the lymph nodes behind the peritoneum, or both. Stage 4 means the cancer has spread to organs outside the peritoneum. As you deal with a diagnosis of ovarian cancer, continue to talk to your doctor and your cancer care team.

ANH15160